For the quarter ending 2025-09-30, CRBP had $6,939K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -23,342 | -34,640 |
| Stock-based compensation expense | 1,582 | 3,277 |
| Depreciation expense | 50 | 134 |
| Net amortization of premiums and discounts on investments | 50 | 624 |
| Amortization of debt discount | 0 | 0 |
| Other | -47 | 289 |
| Decrease in prepaid expenses and other current assets | -2,656 | 2,319 |
| Decrease in other assets | 0 | 0 |
| Decrease in operating lease right-of-use assets | -267 | -509 |
| Decrease in other long-term liabilities | 0 | 0 |
| Decrease in accounts payable | -1,276 | -509 |
| Increase (decrease) in accrued expenses | 4,923 | 2,224 |
| Decrease in operating lease liabilities | -407 | -783 |
| Net cash used in operating activities | -15,550 | -33,020 |
| Purchases of investments | 17,841 | 55,228 |
| Proceeds from sales and maturities of investments | 37,479 | 91,094 |
| Net cash provided by (used in) investing activities | 19,638 | 35,866 |
| Proceeds from issuance of common stock, net | 2,851 | 0 |
| Repayment of notes payable | 0 | 0 |
| Repayment of long-term borrowings | 0 | 0 |
| Net cash provided by financing activities | 2,851 | 0 |
| Net increase in cash, cash equivalents, and restricted cash | 6,939 | 2,846 |
| Cash and cash equivalents at beginning of period | 17,868 | - |
| Cash and cash equivalents at end of period | 27,653 | - |
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Corbus Pharmaceuticals Holdings, Inc. (CRBP)